drugset / Trial / NCT01832870

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

NCT01832870

Phase 1 Completed 9 enrolled Prostate Oncology Specialists, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for patients with advanced prostate cancer.

Timeline

Start
2013-04
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Sipuleucel-T Cell therapy
Background Ipilimumab Monoclonal antibody